Brenner BM . Nephron adaptation to renal injury or ablation. American Journal of Physiology-Renal Physiology 1985; 249:F324–F337.

• PubMed
Brenner BM . Nephron adaptation to renal injury or ablation. American Journal of Physiology-Renal Physiology 1985; 249:F324–F337.)| false
• Search Google Scholar
• Export Citation

Vallon V , et al.. Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10:2569–2576.

• PubMed
Vallon V , . Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10:2569–2576.)| false
• Search Google Scholar
• Export Citation

Thomson SC , et al.. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302:R75–R83.

• PubMed
Thomson SC , . Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302:R75–R83.)| false
• Search Google Scholar
• Export Citation

Vallon V , et al.. Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol-Renal Physiol 2012; 304:F156–F167.

• PubMed
Vallon V , . Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus. Am J Physiol-Renal Physiol 2012; 304:F156–F167.)| false
• Search Google Scholar
• Export Citation

Vallon V , et al.. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol-Renal Physiol 2014; 306:F194–F204.

• PubMed
Vallon V , . SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol-Renal Physiol 2014; 306:F194–F204.)| false
• Search Google Scholar
• Export Citation

Food and Drug Administration. FDA Background Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; 2018.

• PubMed
Food and Drug Administration. FDA Background Document: Endocrinologic and Metabolic Drugs Advisory Committee Meeting; 2018.)| false
• Search Google Scholar
• Export Citation

Zinman B , et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128.

• PubMed
Zinman B , . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117–2128.)| false
• Search Google Scholar
• Export Citation

Neal B , et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644–657.

• PubMed
Neal B , . Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377:644–657.)| false
• Search Google Scholar
• Export Citation

Wiviott SD , et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–357.

• PubMed
Wiviott SD , . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380:347–357.)| false
• Search Google Scholar
• Export Citation

Perkovic V , et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.

• PubMed
Perkovic V , . Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.)| false
• Search Google Scholar
• Export Citation

Wanner C , et al.. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323–334.

• PubMed
Wanner C , . Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323–334.)| false
• Search Google Scholar
• Export Citation

Mazidi Mohsen , et al.. Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22,528 patients. J Am Heart Assoc 2017; 6:6.

• PubMed
Mazidi Mohsen , . Effect of sodium-glucose cotransporter-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: A systematic review and meta-analysis of 43 randomized control trials with 22,528 patients. J Am Heart Assoc 2017; 6:6.)| false
• Search Google Scholar
• Export Citation

American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes–2019. Diabetes Care 2019; 42:S103–S123.

• PubMed
American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes–2019. Diabetes Care 2019; 42:S103–S123.)| false
• Search Google Scholar
• Export Citation

Strippoli GF , et al.. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; Oct 18:CD006257.

• PubMed
Strippoli GF , . Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006; Oct 18:CD006257.)| false
• Search Google Scholar
• Export Citation

Cheng J , et al.. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: A meta-analysis. JAMA Intern Med 2014; 174:773–785.

• PubMed
Cheng J , . Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: A meta-analysis. JAMA Intern Med 2014; 174:773–785.)| false
• Search Google Scholar
• Export Citation